New drug hopes to ease rare Heart-Lung condition

NCT ID NCT07498803

Not yet recruiting Disease control Sponsor: Philipps University Marburg Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests a drug called sotatercept in 40 adults with congenital heart disease and Eisenmenger syndrome, a serious condition where blood flow in the lungs is blocked. The drug is given as a shot every three weeks for 24 weeks. The goal is to see if it safely lowers pressure in the lung arteries and improves how well patients can function.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: sotatercept (a drug that blocks a protein called activin to help blood vessels in the lungs relax)
What this could lead to: If it works, this could point toward a new treatment option to improve lung blood flow and exercise ability in people with Eisenmenger syndrome.
What could go wrong: This is a small, early-phase study with only 40 participants and no placebo group, so results may not apply broadly. The drug may cause side effects like bleeding or low blood pressure.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CONGENITAL HEART DISEASE (CHD) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

congenital heart disease Eisenmenger syndrome pulmonary arterial hypertension

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CONGENITAL HEART DISEASE (CHD) EISENMENGER SYNDROME PAH

More trials for these conditions

Other studies related to the condition(s) this trial covers.